Sartorius Stedim Biotech and RAUMEDIC Sign Partnership Agreement
|| Print ||
|Thursday, 19 May 2011 13:30 (UTC + 2)|
Goettingen, Germany and Helmbrechts, Germany, May 19, 2011 / B3C newswire / – Sartorius Stedim Biotech (SSB), an international leading pharma and biotech supplier, and RAUMEDIC, a leading worldwide OEM manufacturer of medical- and pharmaceutical-grade polymer components and systems, announced the signing of a global partnership agreement. This covers arrangements concerning the mutual development of innovative fluid systems and marketing of single-use tubing, which RAUMEDIC produces for and will supply to Sartorius Stedim Biotech on a long-term basis. Sartorius Stedim Biotech will be combining its designing, manufacturing and validation expertise in single-use systems for biopharmaceutical applications with RAUMEDIC proficiency in the development and manufacture of tubing for medical and biopharmaceutical use. The alliance will provide innovative, high-quality and reliable fluid handling systems to biopharmaceutical manufacturers. Through this strategic partnership with RAUMEDIC, Sartorius Stedim Biotech will substantially expand its product and service portfolio in the area of liquid transfer technologies.
The companies will strengthen and develop their existing long-term collaboration and merge their expertise for generating new tubing technologies and validation standards. With a new product line, TuFlux, which will soon be launched, Sartorius Stedim Biotech will supply its customers with highly validated polymer and silicone tubing on single-use assemblies as well as stand-alone tubing coils, along with comprehensive validation packages. According to the agreement, Sartorius Stedim Biotech will offer its products backed by RAUMEDIC’s support and assistance in order to develop customized solutions and to provide stronger validation and technical support as well as process improvements.
RAUMEDIC is bringing to Sartorius Stedim Biotech more than 60 years of technical expertise and manufacturing excellence in the area of polymer-based systems and components for medical and pharmaceutical applications. The company is renown in material development, compounding of raw materials, and extrusion technologies of all kinds for polymer and elastomer tubing.
Martin Bayer, CEO of RAUMEDIC, explained the benefits for the biopharmaceutical customers. “This alliance will provide integrated, single-use systems to the global biopharmaceutical industry, which have been developed and harmonized by two strong partners in this area,” he said.
This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbour certain risks and uncertainties.
RAUMEDIC’s expertise in material science, design, prototyping, tool making, engineering, R&D and Regulatory Affairs means successful development from customer concept to full CE marked products. Customer satisfaction and adherence to all relevant legal and official requirements are at the centre of the company’s approach to quality. The basis for this is given with clean-room production according to ISO 14644 class 7 and a quality management system certified to ISO 13485.
Sartorius Stedim Biotech